Paclitaxel inhibits killing by murine cytotoxic T lymphocytes in vivo but not in vitro

Immunology and Cell Biology

Volumn 88, Issue 3, 2010, Pages 291-296

  Robinson, Marcus James ^a   Ronchese, Franca ^b   Miller, John H ^a   La Flamme, Anne Camille ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; GAMMA INTERFERON; PACLITAXEL; PELORUSIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CELL KILLING; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; DRUG DOSE COMPARISON; IMMUNE DYSREGULATION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTOTOXICITY; MALE; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PROTEIN STABILITY; SECRETORY GRANULE; SINGLE DRUG DOSE; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS; CLONAL DELETION; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERFERON-GAMMA; MICE; MICE, TRANSGENIC; MICROTUBULES; MITOSIS; MODELS, IMMUNOLOGICAL; PACLITAXEL; SECRETORY VESICLES; T-LYMPHOCYTES, CYTOTOXIC; TUBULIN MODULATORS;

MURINAE; MUS;

EID: 77949875924     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2009.96     Document Type: Article

References (43)

1. Breart B, Lematre F, Celli S, Bousso P. Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest 2008; 118: 1390-1397.
2. Roberts AD, Woodland DL. Cutting edge: Effector memory CD8+ T cells play a prominent role in recall responses to secondary viral infection in the lung. J Immunol 2004; 172: 6533-6537.
3. Stinchcombe JC, Bossi G, Booth S, Griffiths GM. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 2001; 15: 751-761.
4. Stinchcombe JC, Majorovits E, Bossi G, Fuller S, Griffiths GM. Centrosome polarization delivers secretory granules to the immunological synapse. Nature 2006; 443: 462-465.
5. Kuhn JR, Poenie M. Dynamic polarization of the microtubule cytoskeleton during CTL-mediated killing. Immunity 2002; 16: 111-121.
6. Stinchcombe JC, Barral DC, Mules EH, Booth S, Hume AN, Machesky LM et al. Rab27a is required for regulated secretion in cytotoxic T lymphocytes. J Cell Biol 2001; 152: 825-833.
7. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265.
8. Kupfer A, Dennert G. Reorientation of the microtubule-organizing center and the Golgi apparatus in cloned cytotoxic lymphocytes triggered by binding to lysable target cells. J Immunol 1984; 133: 2762-2766.
9. Wolberg G, Stopford CR, Zimmerman TP. Antagonism by taxol of effects of microtubuledisrupting agents on lymphocyte cAMP metabolism and cell function. Proc Natl Acad Sci USA 1984; 81: 3496-3500.
10. Bunnell SC, Kapoor V, Trible RP, Zhang W, Samelson LE. Dynamic actin polymerization drives T cell receptor-induced spreading: a role for the signal transduction adaptor LAT. Immunity 2001; 14: 315-329.
11. Das V, Nal B, Dujeancourt A, Thoulouze M-I, Galli T, Roux P et al. Activation-induced polarized recycling targets T cell antigen receptors to the immunological synapse: involvement of SNARE complexes. Immunity 2004; 20: 577-588.
12. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665-667.
13. Hood KA, West LM, Rouwé B, Northcote PT, Berridge MV, Wakefield SJ et al. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res 2002; 62: 3356-3360.
14. Freedman H, Huzil JT, Luchko T, Luduena RF, Tuszynski JA. Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity. J ChemInf Model 2009; 49: 424-436.
15. Gaitanos TN, Buey RM, Fernando Diáz J, Northcote PT, Teesdale-Spittle P, Andreu JM et al. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res 2004; 64: 5063-5067.
16. Crume KP, Miller JH, La Flamme AC. Peloruside A, an antimitotic agent, specifically decreases tumor necrosis factor-alpha production by lipopolysaccharide-stimulated murine macrophages. Exp Biol Med 2007; 232: 607-613.
17. Chuang LT, Lotzova E, Heath J, Cook KR, Munkarah A, Morris M et al. Alteration of lymphocyte microtubule assembly, cytotoxicity, and activation by the anticancer drug Taxol. Cancer Res 1994; 54: 1286-1291.
18. Markasz L, Skribek H, Uhlin M, Otvos R, Flaberg E, Eksborg S et al. Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. J Immunother 2008; 31: 283-293.
19. Knox JD, Mitchel REJ, Brown DL. Effects of taxol and taxol/hyperthermia treatments on the functional polarization of cytotoxic T lymphocytes. Cell Motil Cytoskeleton 1993; 24: 129-138.
20. Brown DL, Little JE, Chaly N, Schweitzer I, Paulinlevasseur M. Effects of Taxol on microtubule organization in mouse splenic lymphocytes and on response to mitogenic stimulation. Eur J Cell Biol 1985; 37: 130-139.
21. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65-78.
22. Wiedemann A, Depoil D, Faroudi M, Valitutti S. Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses. Proc Natl Acad Sci USA 2006; 103: 10985-10990.
23. Hermans IF, Silk JD, Yang J, Palmowski MJ, Gileadi U, McCarthy C et al. The VITAL assay: A versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods 2004; 285: 25-40.
24. Poenie M, Kuhn J, Combs J. Real-time visualization of the cytoskeleton and effector functions in T cells. Curr Opin Immunol 2004; 16: 428-438.
25. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-9556.
26. Faroudi M, Utzny C, Salio M, Cerundolo V, Guiraud M, Muller S et al. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: Manifestation of a dual activation threshold. Proc Natl Acad Sci USA 2003; 100: 14145-14150.
27. Mirzapoiazova T, Kolosova IA, Moreno L, Sammani S, Garcia JGN, Verin AD. Suppression of endotoxin-induced inflammation by taxol. Eur Respir J 2007; 30: 429-435.
28. Chuang LT. Alteration of lymphocyte microtubule assembly, cytotoxicity, and activation by the anticancer drug Taxol (VOL 54, PG 1286, 1994). Cancer Res 1994; 54: 2523-2524.
29. Zhao C, Morgan M, Haeryfar SMM, Blay J, Hoskin DW. Exposure to paclitaxel or vinblastine down-regulates CD11a and CD54 expression by P815 mastocytoma cells and renders the tumor cells resistant to killing by nonspecific cytotoxic T lymphocytes induced with anti-CD3 antibody. Cancer Immunol Immunother 2003; 52: 185-193.
30. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: Effects of docetaxel on immune enhancement. Clin Cancer Res 2008; 14: 3536-3544.
31. Yu B, Kusmartsev S, Cheng FD, Paolini M, Nefedova Y, Sotomayor E et al. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res 2003; 9: 285-294.
32. Chu Y, Wang LX, Yang G, Ross HJ, Urba WJ, Prell R et al. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother 2006; 29: 367-380.
33. Zhong H, Han B, Tourkova IL, Lokshin A, Rosenbloom A, Shurin MR et al. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res 2007; 13: 5455-5462.
34. Zhang L, Dermawan K, Jin ML, Liu RJ, Zheng HR, Xu L et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol 2008; 129: 219-229.
35. Boukovinas I, Souglakos J, Hatzidaki D, Kakolyris S, Ziras N, Vamvakas L et al. Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: A multicenter phase II study. Lung Cancer 2009; 63: 77-82.
36. Bunn Jr PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 4: 1087-1100.
37. Ringel I, Horwitiz SB. Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288-291.
38. Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 2009; 58: 615-628.
39. Radoja S, Saio M, Schaer D, Koneru M, Vukmanovic S, Frey AB. CD8+ tumorinfiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J Immunol 2001; 167: 5042-5051.
40. Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, von Boehmer H et al. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 2006; 25: 129-141.
41. West LM, Northcote PT, Battershill CN. Peloruside A: A potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem 2000; 65: 445-449.
42. Garrigan K, Moroni-Rawson P, McMurray C, Hermans I, Abernethy N, Watson J et al. Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors. Blood 1996; 88: 3508-3512.
43. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991; 145: 185-192.